KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Integrated multi-omics characterization of KRAS mutant colorectal cancer
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer: Cell
Frontiers | Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Correlation between clinical data and molecular marker alterations in... | Download Scientific Diagram
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
A): Dynamic change in tumor marker (CA125) (blue line) and KRAS G12V... | Download Scientific Diagram
KRAS drives immune evasion in a genetic model of pancreatic cancer | Nature Communications
Immune modulatory effects of oncogenic KRAS in cancer | Nature Communications
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge | Cell Discovery
KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer - ScienceDirect
KRAS mutation A treatment target
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Molecular epidemiology and diagnostics of KRAS mutations in human cancer | SpringerLink
Targeting KRAS mutant cancers: from druggable therapy to drug resistance | Molecular Cancer | Full Text
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
KRAS mutations predict response to EGFR inhibitors - ScienceDirect
KRAS Screening & Profiling
